Compare EVC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | AUTL |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.9M | 596.2M |
| IPO Year | 2000 | 2025 |
| Metric | EVC | AUTL |
|---|---|---|
| Price | $6.50 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 47.59 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $536,034,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $98.68 |
| Revenue Next Year | N/A | $28.47 |
| P/E Ratio | $19.02 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.98 | $1.18 |
| 52 Week High | $13.74 | $2.58 |
| Indicator | EVC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 31.30 |
| Support Level | $6.43 | $1.38 |
| Resistance Level | $10.09 | $1.73 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 63.64 | 6.87 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.